Literature DB >> 9107180

Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.

K C Wollert1, R Studer, K Doerfer, E Schieffer, C Holubarsch, H Just, H Drexler.   

Abstract

BACKGROUND: Left ventricular remodeling after myocardial infarction (MI) involves the hypertrophic growth of cardiomyocytes and the accumulation of fibrillar collagen in the interstitial space. We evaluated the role of kinins in postinfarction ventricular remodeling and their potential contribution to the antiremodeling effects of ACE inhibition and angiotensin II type 1 (AT1) receptor blockade. METHODS AND
RESULTS: Rats underwent coronary artery ligation followed by chronic B2 kinin receptor blockade with icatibant. Additional groups of infarcted rats were treated with the ACE inhibitor lisinopril or the AT1 receptor antagonist ZD7155, each separately and in combination with icatibant. B2 kinin receptor blockade enhanced the interstitial deposition of collagen after MI, whereas morphological and molecular markers of cardiomyocyte hypertrophy (cardiac weight, myocyte cross-sectional area, prepro-atrial natriuretic factor mRNA expression) were not affected. Chronic ACE inhibition and AT1 receptor blockade reduced collagen deposition and cardiomyocyte hypertrophy after MI. The inhibitory action of ACE inhibition and AT1 receptor blockade on interstitial collagen was partially reversed by B2 kinin receptor blockade. However, B2 kinin receptor blockade did not attenuate the effects of ACE inhibition and AT1 receptor blockade on cardiomyocyte hypertrophy.
CONCLUSIONS: (1) Kinins inhibit the interstitial accumulation of collagen but do not modulate cardiomyocyte hypertrophy after MI. (2) Kinins contribute to the reduction of myocardial collagen accumulation by ACE inhibition and AT1 receptor blockade. (3) The effects of ACE inhibition and AT1 receptor blockade on cardiomyocyte hypertrophy are related to a reduced generation/receptor blockade of angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9107180     DOI: 10.1161/01.cir.95.7.1910

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.

Authors:  D Reinhardt; H H Sigusch; J Hensse; S C Tyagi; R Körfer; H R Figulla
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

Review 2.  Targeting signaling pathways in heart failure by gene transfer.

Authors:  Briain D MacNeill; Motoya Hayase; Roger J Hajjar
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

3.  Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction.

Authors:  Florian Leuschner; Peter Panizzi; Isabel Chico-Calero; Won Woo Lee; Takuya Ueno; Virna Cortez-Retamozo; Peter Waterman; Rostic Gorbatov; Brett Marinelli; Yoshiko Iwamoto; Aleksey Chudnovskiy; Jose-Luiz Figueiredo; David E Sosnovik; Mikael J Pittet; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circ Res       Date:  2010-10-07       Impact factor: 17.367

4.  Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.

Authors:  Yu-Yu Yao; Hang Yin; Bo Shen; Lee Chao; Julie Chao
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

5.  AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.

Authors:  Quang T Nguyen; Federico Colombo; Robert Clement; Hugues Gosselin; Jean-Lucien Rouleau; Angelino Calderone
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

6.  Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR.

Authors:  Shant Der Sarkissian; Eve-Lyne Marchand; David Duguay; Denis deBlois
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 7.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

8.  Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse.

Authors:  C Emanueli; M Bonaria Salis; C Figueroa; J Chao; L Chao; L Gaspa; M C Capogrossi; P Madeddu
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

9.  p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.

Authors:  Ahmed Fahmi; Nicola Smart; Anu Punn; Rita Jabr; Michael Marber; Richard Heads
Journal:  Cell Signal       Date:  2012-12-23       Impact factor: 4.315

10.  Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.

Authors:  Qin Shi; Jamilah Abusarah; Ghayath Baroudi; Julio C Fernandes; Hassan Fahmi; Mohamed Benderdour
Journal:  Arthritis Res Ther       Date:  2012-10-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.